Related Experiment Video
Updated: Mar 25, 2026
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Evaluating pozelimab in the treatment of CHAPLE disease
Necmiye Keser Ozturk1,2,3,4, Durmus Burak Demirkaya1,2,3,4, Alper Bulutoglu1,2,3,4
1Faculty of Medicine, Department of Pediatrics, Division of Allergy and Immunology, Marmara University, Istanbul, Türkiye.
Insights
Pozelimab, an anti-C5 therapy, effectively treats CHAPLE disease by inhibiting complement activation. This leads to remission of protein-losing enteropathy and improved patient quality of life.
Area of Science:
- Rare disease genetics and immunology
- Complement system dysregulation
- Therapeutic antibody development
Background:
- CHAPLE disease is a rare, severe disorder caused by CD55 gene mutations, leading to complement system overactivation.
- Clinical manifestations include protein-losing enteropathy, edema, infections, thrombosis, and failure to thrive.
- Complement-mediated endothelial injury drives thrombotic risk in CHAPLE disease.
Purpose of the Study:
- To review the role of pozelimab in managing CHAPLE disease.
- To discuss the mechanistic basis and clinical evidence for pozelimab therapy.
- To highlight the impact of pozelimab on patient-centered care.
Main Methods:
- Review of clinical evidence and mechanistic studies on pozelimab in CHAPLE disease.
- Analysis of treatment outcomes including remission of protein-losing enteropathy and quality of life.
- Discussion of U.S. FDA approval and therapeutic implications.
Main Results:
- Pozelimab, a C5 inhibitor, effectively targets complement activation in CHAPLE disease.
- Treatment leads to sustained remission of protein-losing enteropathy, reducing albumin replacement needs.
- Pozelimab improves symptom control, nutritional status, and quality of life, reducing hospitalizations.
Conclusions:
- Pozelimab represents a significant advancement in CHAPLE disease treatment.
- Targeting the complement system with pozelimab offers a rational and effective therapeutic strategy.
- Pozelimab enhances patient outcomes and quality of life in CHAPLE disease.
Abstract:
CHAPLE disease (Complement Hyperactivation, Angiopathic Thrombosis, and Protein-Losing Enteropathy [PLE]) is a rare, life-threatening disorder caused by biallelic mutations in the CD55 gene, which encodes decay-accelerating factor, a key regulator of the complement system. The disease typically manifests in early childhood with hypoalbuminemic edema, gastrointestinal symptoms, recurrent infections, and failure to thrive, alongside an elevated thrombotic risk due to complement-mediated endothelial injury and coagulation activation. Given these pathogenetic mechanisms, complement-targeted therapies have emerged as a rational approach to disease management. Eculizumab, a monoclonal antibody against complement component C5, initially demonstrated clinical benefit when administered on a compassionate-use basis. Building upon this success, pozelimab, a next-generation subcutaneous anti-C5 monoclonal antibody, was evaluated in CHAPLE patients and subsequently received U.S. FDA approval for this indication. Pozelimab effectively inhibits terminal complement activation, leading to sustained remission of PLE, obviating the need for albumin replacement, reducing hospitalization rates, improving symptom control and nutritional status, and ultimately enhancing overall quality of life. This review highlights the evolving role of pozelimab in CHAPLE disease by discussing its mechanistic basis, emerging clinical evidence, and implications for patient-centered care.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...